PLGA(50:50)(50,000)-b-mPEG (1,500), Diblock polymer, Powder

Product Number:

CAS #

CAS #                 Product #

    50349

Size

Price

$318.00

Quantity

Bulk Request

Request a Bulk Quote 

Product Specifications

    No Product Specifications

Linear Formula
    [C3H4O2]m[C2H2O2]n[C2H4O]x 
Appearance
    White to off-white to light tan powder
Biodegradation Time
    Months
Safety Data Sheet (SDS)
Handling
    Gloves & fume hood
Storage
    Protect from moisture. Store at -20°C.
Hazards
    Harmless - use normal precautions; Hygroscopic
Related Documents

    SpecSheet_50349

Related Documents

    1. Panagi, Z., Beletsi, A., Evangelatos, G., Livaniou, E., Ithakissios, D. S., & Avgoustakis, K. (2001). Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles. International journal of pharmaceutics, 221(1-2), 143-152.

    2. Cheng, L., Jin, C., Lv, W., Ding, Q., & Han, X. (2011). Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PloS one, 6(9), e25433.

    3. Ashjari, M., Panahandeh, F., Niazi, Z., & Abolhasani, M. M. (2020). Synthesis of PLGA–mPEG star-like block copolymer to form micelle loaded magnetite as a nanocarrier for hydrophobic anticancer drug. Journal of Drug Delivery Science and Technology, 56, 101563.
    4. Shen, X., Li, T., Xie, X., Feng, Y., Chen, Z., Yang, H., ... & Liu, Y. (2020). PLGA-based drug delivery systems for remotely triggered cancer therapeutic and diagnostic applications. Frontiers in Bioengineering and Biotechnology, 8, 381.

    5. Rocha, C. V., Gonçalves, V., da Silva, M. C., Bañobre-López, M., & Gallo, J. (2022). PLGA-based composites for various biomedical applications. International Journal of Molecular Sciences, 23(4), 2034.

PLGA(50:50)(50,000) - b - mPEG (1,500), Diblock polymer, Powder - Polysciences
PLGA(50:50)(50,000) - b - mPEG (1,500), Diblock polymer, Powder - Polysciences

Product Description

High-grade, suitable for biomedical research.
Supplied as micronized powder.
(Poly(lactic-co-glycolic acid)-b-polyethylene glycol) (PLGA-b-mPEG) is a biodegradable and amphiphilic block copolymer composed of poly(lactic-co-glycolic acid) (PLGA), a widely used biodegradable polymer, and polyethylene glycol (PEG), known for its hydrophilic and biocompatible properties. The copolymer combines the controlled degradation of PLGA with the solubilizing and biocompatibility-enhancing effects of PEG. The ratio of lactic acid to glycolic acid in the PLGA segment, as well as the molecular weight of both PLGA and PEG, can be tailored to modulate degradation rates, mechanical properties, and hydrophilic-lipophilic balance.
This copolymer finds extensive use in drug delivery systems, especially in creating nanoparticles, micelles, and hydrogels, where its amphiphilic nature allows for effective encapsulation and controlled release of hydrophobic drugs. The PEG component increases water solubility and minimizes protein adsorption, improving circulation time and reducing immune system recognition. PLGA-b-mPEG is particularly advantageous in applications such as cancer therapeutics, tissue engineering, and bioactive scaffolds, where it enables tunable degradation and biocompatibility for implantable devices. Its versatility makes it a favored material for developing advanced biomedical applications requiring precise control over material properties and drug delivery kinetics.
Synonyms/Acronyms:
PLGA-b-mPEG PLGA-mPEG
PLGA(50:50)(50,000) - b - mPEG (1,500), Diblock polymer, Powder - Polysciences
PLGA(50:50)(50,000) - b - mPEG (1,500), Diblock polymer, Powder - Polysciences
Product Specifications

    No Product Specifications

Linear Formula
    [C3H4O2]m[C2H2O2]n[C2H4O]x 
Appearance
    White to off-white to light tan powder
Biodegradation Time
    Months
Safety Data Sheet (SDS)
Handling
    Gloves & fume hood
Storage
    Protect from moisture. Store at -20°C.
Hazards
    Harmless - use normal precautions; Hygroscopic
Related Documents

    SpecSheet_50349

References

    1. Panagi, Z., Beletsi, A., Evangelatos, G., Livaniou, E., Ithakissios, D. S., & Avgoustakis, K. (2001). Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles. International journal of pharmaceutics, 221(1-2), 143-152.

    2. Cheng, L., Jin, C., Lv, W., Ding, Q., & Han, X. (2011). Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PloS one, 6(9), e25433.

    3. Ashjari, M., Panahandeh, F., Niazi, Z., & Abolhasani, M. M. (2020). Synthesis of PLGA–mPEG star-like block copolymer to form micelle loaded magnetite as a nanocarrier for hydrophobic anticancer drug. Journal of Drug Delivery Science and Technology, 56, 101563.
    4. Shen, X., Li, T., Xie, X., Feng, Y., Chen, Z., Yang, H., ... & Liu, Y. (2020). PLGA-based drug delivery systems for remotely triggered cancer therapeutic and diagnostic applications. Frontiers in Bioengineering and Biotechnology, 8, 381.

    5. Rocha, C. V., Gonçalves, V., da Silva, M. C., Bañobre-López, M., & Gallo, J. (2022). PLGA-based composites for various biomedical applications. International Journal of Molecular Sciences, 23(4), 2034.